Medifast (MED) Competitors

$12.48 -0.09 (-0.72%)

Closing price 05/13/2026 03:59 PM Eastern

Extended Trading

$12.54 +0.06 (+0.52%)

As of 07:36 AM Eastern

MED vs. LW, NOMD, NATR, USNA, and NUS

Should you buy Medifast stock or one of its competitors? MarketBeat compares Medifast with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medifast include Lamb Weston (LW), Nomad Foods (NOMD), Nature's Sunshine Products (NATR), USANA Health Sciences (USNA), and Nu Skin Enterprises (NUS).

How does Medifast compare to Lamb Weston?

Medifast (NYSE:MED) and Lamb Weston (NYSE:LW) are both consumer staples companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

95.5% of Medifast shares are held by institutional investors. Comparatively, 89.6% of Lamb Weston shares are held by institutional investors. 3.7% of Medifast shares are held by company insiders. Comparatively, 0.3% of Lamb Weston shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Lamb Weston had 1 more articles in the media than Medifast. MarketBeat recorded 6 mentions for Lamb Weston and 5 mentions for Medifast. Medifast's average media sentiment score of 0.99 beat Lamb Weston's score of 0.58 indicating that Medifast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medifast	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lamb Weston	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medifast presently has a consensus price target of $12.00, indicating a potential downside of 3.85%. Lamb Weston has a consensus price target of $48.00, indicating a potential upside of 15.61%. Given Lamb Weston's stronger consensus rating and higher probable upside, analysts plainly believe Lamb Weston is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Lamb Weston	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.15

Lamb Weston has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Lamb Weston, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$385.79M	0.36	-$18.67M	-$1.83	N/A
Lamb Weston	$6.45B	0.89	$357.20M	$2.14	19.40

Lamb Weston has a net margin of 4.61% compared to Medifast's net margin of -5.78%. Lamb Weston's return on equity of 23.77% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-5.78%	-4.80%	-3.83%
Lamb Weston	4.61%	23.77%	5.76%

Medifast has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Lamb Weston has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Summary

Lamb Weston beats Medifast on 12 of the 16 factors compared between the two stocks.

How does Medifast compare to Nomad Foods?

Medifast (NYSE:MED) and Nomad Foods (NYSE:NOMD) are both small-cap consumer staples companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

95.5% of Medifast shares are owned by institutional investors. Comparatively, 75.3% of Nomad Foods shares are owned by institutional investors. 3.7% of Medifast shares are owned by insiders. Comparatively, 17.3% of Nomad Foods shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Nomad Foods had 6 more articles in the media than Medifast. MarketBeat recorded 11 mentions for Nomad Foods and 5 mentions for Medifast. Medifast's average media sentiment score of 0.99 beat Nomad Foods' score of 0.34 indicating that Medifast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medifast	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nomad Foods	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Medifast currently has a consensus target price of $12.00, suggesting a potential downside of 3.85%. Nomad Foods has a consensus target price of $12.50, suggesting a potential upside of 37.53%. Given Nomad Foods' stronger consensus rating and higher probable upside, analysts clearly believe Nomad Foods is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Nomad Foods	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Nomad Foods has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nomad Foods, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$385.79M	0.36	-$18.67M	-$1.83	N/A
Nomad Foods	$3.43B	0.38	$154.66M	$1.03	8.82

Nomad Foods has a net margin of 4.43% compared to Medifast's net margin of -5.78%. Nomad Foods' return on equity of 9.05% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-5.78%	-4.80%	-3.83%
Nomad Foods	4.43%	9.05%	3.61%

Medifast has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Nomad Foods has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

Summary

Nomad Foods beats Medifast on 14 of the 16 factors compared between the two stocks.

How does Medifast compare to Nature's Sunshine Products?

Medifast (NYSE:MED) and Nature's Sunshine Products (NASDAQ:NATR) are both small-cap personal products companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

Medifast currently has a consensus target price of $12.00, suggesting a potential downside of 3.85%. Nature's Sunshine Products has a consensus target price of $35.00, suggesting a potential upside of 56.74%. Given Nature's Sunshine Products' stronger consensus rating and higher probable upside, analysts clearly believe Nature's Sunshine Products is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Nature's Sunshine Products	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

95.5% of Medifast shares are owned by institutional investors. Comparatively, 79.4% of Nature's Sunshine Products shares are owned by institutional investors. 3.7% of Medifast shares are owned by insiders. Comparatively, 3.1% of Nature's Sunshine Products shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nature's Sunshine Products has a net margin of 4.06% compared to Medifast's net margin of -5.78%. Nature's Sunshine Products' return on equity of 14.67% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-5.78%	-4.80%	-3.83%
Nature's Sunshine Products	4.06%	14.67%	9.27%

Medifast has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Nature's Sunshine Products has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

In the previous week, Nature's Sunshine Products had 13 more articles in the media than Medifast. MarketBeat recorded 18 mentions for Nature's Sunshine Products and 5 mentions for Medifast. Nature's Sunshine Products' average media sentiment score of 1.29 beat Medifast's score of 0.99 indicating that Nature's Sunshine Products is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medifast	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nature's Sunshine Products	7 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nature's Sunshine Products has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$385.79M	0.36	-$18.67M	-$1.83	N/A
Nature's Sunshine Products	$489.79M	0.80	$19.52M	$1.10	20.30

Summary

Nature's Sunshine Products beats Medifast on 14 of the 16 factors compared between the two stocks.

How does Medifast compare to USANA Health Sciences?

USANA Health Sciences (NYSE:USNA) and Medifast (NYSE:MED) are both small-cap personal products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

In the previous week, USANA Health Sciences had 2 more articles in the media than Medifast. MarketBeat recorded 7 mentions for USANA Health Sciences and 5 mentions for Medifast. Medifast's average media sentiment score of 0.99 beat USANA Health Sciences' score of 0.57 indicating that Medifast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
USANA Health Sciences	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medifast	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

USANA Health Sciences has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
USANA Health Sciences	$925.26M	0.35	$10.76M	$0.47	37.43
Medifast	$385.79M	0.36	-$18.67M	-$1.83	N/A

Medifast has a consensus target price of $12.00, suggesting a potential downside of 3.85%. Given Medifast's higher probable upside, analysts clearly believe Medifast is more favorable than USANA Health Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
USANA Health Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

54.3% of USANA Health Sciences shares are held by institutional investors. Comparatively, 95.5% of Medifast shares are held by institutional investors. 0.8% of USANA Health Sciences shares are held by insiders. Comparatively, 3.7% of Medifast shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

USANA Health Sciences has a net margin of 0.96% compared to Medifast's net margin of -5.78%. USANA Health Sciences' return on equity of 6.21% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
USANA Health Sciences	0.96%	6.21%	4.50%
Medifast	-5.78%	-4.80%	-3.83%

USANA Health Sciences has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Medifast has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

Summary

USANA Health Sciences beats Medifast on 9 of the 14 factors compared between the two stocks.

How does Medifast compare to Nu Skin Enterprises?

Nu Skin Enterprises (NYSE:NUS) and Medifast (NYSE:MED) are both small-cap consumer staples companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Nu Skin Enterprises has a net margin of 3.78% compared to Medifast's net margin of -5.78%. Nu Skin Enterprises' return on equity of 7.47% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nu Skin Enterprises	3.78%	7.47%	4.21%
Medifast	-5.78%	-4.80%	-3.83%

Nu Skin Enterprises has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Medifast has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

82.8% of Nu Skin Enterprises shares are held by institutional investors. Comparatively, 95.5% of Medifast shares are held by institutional investors. 2.8% of Nu Skin Enterprises shares are held by insiders. Comparatively, 3.7% of Medifast shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Nu Skin Enterprises has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nu Skin Enterprises, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nu Skin Enterprises	$1.49B	0.20	$160.20M	$1.10	5.73
Medifast	$385.79M	0.36	-$18.67M	-$1.83	N/A

In the previous week, Nu Skin Enterprises had 10 more articles in the media than Medifast. MarketBeat recorded 15 mentions for Nu Skin Enterprises and 5 mentions for Medifast. Medifast's average media sentiment score of 0.99 beat Nu Skin Enterprises' score of -0.04 indicating that Medifast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nu Skin Enterprises	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medifast	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nu Skin Enterprises	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Nu Skin Enterprises beats Medifast on 10 of the 15 factors compared between the two stocks.

Get Medifast News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MED vs. The Competition

Export

Metric	Medifast	FOOD Industry	Staples Sector	NYSE Exchange
Market Cap	$139.77M	$7.44B	$16.24B	$22.95B
Dividend Yield	N/A	4.18%	3.49%	4.06%
P/E Ratio	-6.82	15.37	23.21	28.29
Price / Sales	0.36	1.14	47.69	24.50
Price / Cash	30.28	9.75	16.36	25.11
Price / Book	0.70	2.50	5.25	4.73
Net Income	-$18.67M	$224.26M	$674.08M	$1.07B
7 Day Performance	-1.21%	-3.81%	-2.71%	-1.11%
1 Month Performance	14.92%	-4.71%	-3.12%	1.36%
1 Year Performance	-2.35%	-12.94%	-12.24%	24.41%

Medifast Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MED Medifast	2.0177 of 5 stars	$12.48 -0.7%	$12.00 -3.8%	-2.0%	$139.77M	$385.79M	N/A	870
LW Lamb Weston	4.5559 of 5 stars	$43.93 +0.9%	$48.00 +9.3%	-18.9%	$6.06B	$6.45B	20.53	10,100
NOMD Nomad Foods	4.9098 of 5 stars	$9.51 -2.1%	$12.50 +31.4%	-50.8%	$1.35B	$3.43B	9.33	7,752	News Coverage Earnings Report Analyst Upgrade High Trading Volume
NATR Nature's Sunshine Products	4.2185 of 5 stars	$26.66 -1.8%	$31.00 +16.3%	+55.8%	$466.76M	$480.14M	25.15	850	Positive News Earnings Report Analyst Forecast
USNA USANA Health Sciences	2.4882 of 5 stars	$19.30 +1.3%	N/A	-40.8%	$357.14M	$925.26M	35.09	1,570

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:MED) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medifast (MED) Competitors

MED vs. LW, NOMD, NATR, USNA, and NUS

How does Medifast compare to Lamb Weston?

Summary

How does Medifast compare to Nomad Foods?

Summary

How does Medifast compare to Nature's Sunshine Products?

Summary

How does Medifast compare to USANA Health Sciences?

Summary

How does Medifast compare to Nu Skin Enterprises?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MED vs. The Competition

Medifast Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medifast (MED) Competitors

MED vs. LW, NOMD, NATR, USNA, and NUS

How does Medifast compare to Lamb Weston?

Do institutionals and insiders believe in MED or LW?

Does the media favor MED or LW?

Do analysts prefer MED or LW?

Which has higher valuation & earnings, MED or LW?

Is MED or LW more profitable?

Which has more risk & volatility, MED or LW?

Summary

How does Medifast compare to Nomad Foods?

Do insiders and institutionals have more ownership in MED or NOMD?

Does the media prefer MED or NOMD?

Do analysts recommend MED or NOMD?

Which has higher earnings and valuation, MED or NOMD?

Is MED or NOMD more profitable?

Which has more risk and volatility, MED or NOMD?

Summary

How does Medifast compare to Nature's Sunshine Products?

Do analysts recommend MED or NATR?

Do insiders and institutionals have more ownership in MED or NATR?

Is MED or NATR more profitable?

Which has more risk and volatility, MED or NATR?

Does the media prefer MED or NATR?

Which has higher earnings and valuation, MED or NATR?

Summary

How does Medifast compare to USANA Health Sciences?

Does the media refer more to USNA or MED?

Which has preferable valuation & earnings, USNA or MED?

Do analysts recommend USNA or MED?

Do insiders & institutionals have more ownership in USNA or MED?

Is USNA or MED more profitable?

Which has more volatility & risk, USNA or MED?

Summary

How does Medifast compare to Nu Skin Enterprises?

Is NUS or MED more profitable?

Which has more volatility & risk, NUS or MED?

Do insiders & institutionals have more ownership in NUS or MED?

Which has preferable valuation & earnings, NUS or MED?

Does the media refer more to NUS or MED?

Do analysts recommend NUS or MED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MED vs. The Competition

Medifast Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools